YN480234 Dehydro-ZINC39395747 433248-87-4

Dehydro-ZINC39395747 is a derivative of ZINC39395747. ZINC39395747 is a potent cytochrome b5 reductase 3 (CYB5R3) inhibitor with an IC50 of 9.14μM and a Kdof 1.11μM. ZINC39395747 can increase NO bioavailabili...

YN410015 TRAF-STOP inhibitor 68... 433249-94-6

TRAF-STOP inhibitor 6877002, is a selective inhibitor ofCD40-TRAF6interaction, compound VII, shows inhibition ofNF-κBactivation in RAW cells, extracted from patent WO2014033122A1. TRAF-STOP 6877002 prevent...

YN321849 K41498 434938-41-7

K41498 is a potent and highly selectiveCRF2 receptorantagonist with Ki values of 0.66nM, 0.62nM and 425nM for human CRF2α, CRF2β and CRF1receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30)...

YN320831 Macitentan 441798-33-0

Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.

YN481643 Yoda 1 448947-81-7

Yoda 1 is aPiezo1agonist. Yoda 1 activates purified Piezo1 channels.

YN330369 AVE3085 450348-85-3

AVE3085 is a potent endothelialnitric oxide synthaseenhancer, used for cardiovascular disease treatment.

YN440153 TIE-2/VEGFR-2 kinase-I... 453590-24-4

TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and /or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated w...

YN321314 MRE-269 475085-57-5

MRE-269 is an active metabolite of selexipag, and acts as a selectiveIP receptoragonist.

YN320923 Selexipag 475086-01-2

Selexipag is an orally active, first-in-class, selective prostacyclin IP receptor agonist with Ki value of 260 nM for human IP, whereas Ki values > 10,000 nM are measured at the other human G-protein-coupled prostanoid receptors (...

YN320004 AT2 receptor agonist C21 477775-14-7

AT2 receptor agonist C21 is a druglike selectiveangiotensin II AT2 receptoragonist with Ki values of 0.4nM and >10µM for the AT2 receptor and AT1 receptor, respectively.

YN370925 CUDA 479413-68-8

CUDA is a potent inhibitor ofsoluble epoxide hydrolase (sEH), with IC50s of 11.1nM and 112nM for mouse sEH and human sEH, respectively. CUDA selectively increasesperoxisome proliferator-activated receptor (PPAR) al...

YN370245 Edoxaban 480449-70-5

Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.

YN360384 ORM-10103 488847-28-5

ORM-10103 is a specific inhibitor of theNa+/Ca2+ exchanger (NCX), which decreases the NCX current with estimatedIC50s of 55 and 67nM at -80 and at 20 mV, respectively.

YN370991 SBC-115076 489415-96-5

SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.

YN330305 Eltrombopag 496775-61-2

Eltrombopag, a member of the biarylhydrazone class, is a nonpeptide agonist of the thrombopoietin receptor (TpoR), used to treat chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).

YN330306 Eltrombopag Olamine 496775-62-3

Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).

YN320754 Beraprost sodium 496807-11-5

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug ofPGI2. Beraprost sodium is a potentvasodilator, has the potential for pulmonary arterial hypertension treatment through exp and ing renal vessels, improv...

YN360278 IK1 inhibitor PA-6 500715-03-7

IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potentIK1(KIR2.x ion-channel-carried inward rectifier current) inhibitor, with IC50 values of 12-15nM for human and mouse KIR2.x currents. IK1 inhi...

YN372637 Apixaban 503612-47-3

Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

YN484064 LCKLSL 533902-29-3

LCKLSL is a N-terminal hexapeptide and a competitiveannexin A2 (AnxA2)inhibitor. LCKLSL potently inhibits thebinding of tissue plasminogen activator (tPA)toAnxA2. LCKLSL also inhibits the generation of plasmin a...